Literature DB >> 23475875

Aiming for the outliers: cancer precision medicine through targeting kinases with extreme expression.

Srinivasan Yegnasubramanian1, Anirban Maitra.   

Abstract

With the increasing availability of highly potent, pharmacologically active, and selective protein kinase inhibitors, identification of individuals who would benefit from targeted kinase inhibitors could facilitate application of precision medicine strategies for cancer therapy. A recent study by Kothari and colleagues reports preclinical studies that highlight the potential of targeting kinases with extreme expression for cancer precision medicine, warranting further clinical investigation of an individual-specific outlier kinase targeting approach. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23475875      PMCID: PMC4486056          DOI: 10.1158/2159-8290.CD-13-0016

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  10 in total

Review 1.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

2.  Treating cancer's kinase 'addiction'.

Authors:  José Baselga; Joaquín Arribas
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

Review 3.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

Review 4.  Targeting cancer with small molecule kinase inhibitors.

Authors:  Jianming Zhang; Priscilla L Yang; Nathanael S Gray
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

Review 5.  Treating ALK-positive lung cancer--early successes and future challenges.

Authors:  D Ross Camidge; Robert C Doebele
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

Review 6.  Improving treatment of HER2-positive cancers: opportunities and challenges.

Authors:  Howard M Stern
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

Review 7.  Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

Authors:  Vince D Cataldo; Don L Gibbons; Román Pérez-Soler; Alfonso Quintás-Cardama
Journal:  N Engl J Med       Date:  2011-03-10       Impact factor: 91.245

Review 8.  Kinase mutations in human disease: interpreting genotype-phenotype relationships.

Authors:  Piya Lahiry; Ali Torkamani; Nicholas J Schork; Robert A Hegele
Journal:  Nat Rev Genet       Date:  2010-01       Impact factor: 53.242

9.  Outlier kinase expression by RNA sequencing as targets for precision therapy.

Authors:  Vishal Kothari; Iris Wei; Sunita Shankar; Shanker Kalyana-Sundaram; Lidong Wang; Linda W Ma; Pankaj Vats; Catherine S Grasso; Dan R Robinson; Yi-Mi Wu; Xuhong Cao; Diane M Simeone; Arul M Chinnaiyan; Chandan Kumar-Sinha
Journal:  Cancer Discov       Date:  2013-02-05       Impact factor: 39.397

Review 10.  Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.

Authors:  Elias Jabbour; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2012-11       Impact factor: 10.047

  10 in total
  1 in total

Review 1.  Microchip-based single-cell functional proteomics for biomedical applications.

Authors:  Yao Lu; Liu Yang; Wei Wei; Qihui Shi
Journal:  Lab Chip       Date:  2017-03-29       Impact factor: 6.799

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.